Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 243,885 |
|
|||||
| News | (2) | ||||||
| Day High | 25.9875 | Low High |
|||||
| Day Low | 24.49 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Pharvaris NV | PHVS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.42 | -1.65% | 25.00 | 17:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 25.42 | 24.49 | 25.9875 | 25.00 | 25.42 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,888 | 243,885 | $ 25.44 | $ 6,204,767 | - | 3.85 - 29.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:51:59 | 1 | $ 25.46 | USD |
Pharvaris NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.02B | 40.82M | - | 0 | -76.33M | -1.87 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Pharvaris NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PHVS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 17.36 | 29.80 | 16.81 | 24.61 | 572,907 | 7.64 | 44.01% |
| 1 Month | 16.59 | 29.80 | 15.00 | 22.16 | 208,777 | 8.41 | 50.69% |
| 3 Months | 20.56 | 29.80 | 15.00 | 21.50 | 86,680 | 4.44 | 21.6% |
| 6 Months | 8.26 | 29.80 | 8.25 | 19.28 | 76,545 | 16.74 | 202.66% |
| 1 Year | 4.19 | 29.80 | 3.85 | 11.37 | 491,495 | 20.81 | 496.66% |
| 3 Years | 25.00 | 42.86 | 1.77 | 12.47 | 196,339 | 0.00 | 0.0% |
| 5 Years | 25.00 | 42.86 | 1.77 | 12.47 | 196,339 | 0.00 | 0.0% |
Pharvaris NV Description
| Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. |
